Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

Viral Hepatitis I: Introduction

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

Inhibitors Of Virion Release

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...

Inhibitors of Virion Maturation and Assembly

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...

Viruses with RNA Genomes

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Position on the management of occult infection by hepatitis B virus (OBI) and anti-HBc + in hemodialysis units.

Nefrologia·2025

Same author

Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: Results of a literature review.

Gastroenterologia y hepatologia·2022

Same author

Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid.

Alimentary pharmacology & therapeutics·2020

Same author

Infection with multiple hepatitis C virus genotypes detected using commercial tests should be confirmed using next generation sequencing.

Scientific reports·2019

Same author

HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1.

Open forum infectious diseases·2019

Same author

Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort.

Journal of viral hepatitis·2018

Search research articles

Related Experiment Video

Updated: Jun 27, 2026

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

[Interferon in hepatitis B].

Luisa García Buey¹, Fernando González Mateos, Ricardo Moreno Otero

¹Servicio de Aparato Digestivo, Unidad de Hepatología, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, España. lgarciabuey@medynet.com

Enfermedades Infecciosas Y Microbiologia Clinica

|December 23, 2008

Summary

This summary is machine-generated.

Pegylated interferon-alpha (PEG-IFNalpha) offers effective treatment for chronic hepatitis B (CHB) with limited duration and no antiviral resistance. It shows promise, especially for specific genotypes, but has adverse effects and contraindications.

More Related Videos

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Published on: November 7, 2018

Related Experiment Videos

Last Updated: Jun 27, 2026

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Published on: November 7, 2018

Area of Science:

Hepatology
Virology
Immunology

Background:

Chronic hepatitis B (CHB) is a global health issue affecting 350 million people.
CHB can lead to cirrhosis and liver cancer, causing nearly one million deaths annually.
Current therapeutic options for CHB include standard interferon-alpha (IFN-alpha), pegylated interferon-alpha (PEG-IFNalpha), lamivudine, adefovir, entecavir, and telbivudine.

Purpose of the Study:

To review the therapeutic options for chronic hepatitis B (CHB).
To highlight the advantages and disadvantages of interferon-based therapies.
To explore potential combination strategies for improved treatment outcomes.

Main Methods:

Review of existing literature on CHB treatments.
Analysis of efficacy and safety data for approved therapies.
Discussion of treatment response predictors and limitations.

Main Results:

PEG-IFNalpha is a first-line option for HBeAg(+) and HBeAg(-) CHB, offering limited treatment duration and higher sustained response rates than conventional IFN-alpha.
IFN-based therapies have antiviral and immunomodulatory effects, leading to greater HBeAg and HBsAg clearance.
Optimal response to PEG-IFNalpha is observed in patients with elevated transaminases, moderate viral load, and HBV genotypes A and B.
Adverse effects and contraindications exist, particularly in patients with decompensated cirrhosis.
Combination therapy with nucleos(t)ide analogs and PEG-IFNalpha may enhance sustained response rates but requires further investigation.

Conclusions:

PEG-IFNalpha is an effective treatment for CHB, offering advantages over conventional IFN-alpha.
Patient selection based on viral load, transaminase levels, and HBV genotype can optimize treatment response.
Further research is needed to determine the most effective combination therapeutic strategies for CHB.